Global Human Rabies Immunoglobulin (IM) Competitive Landscape Professional Research Report 2025

Global Human Rabies Immunoglobulin (IM) Competitive Landscape Professional Research Report 2025

Research Summary

Human Rabies Immunoglobulin (HRIG) is a specialized immunoglobulin preparation used in the post-exposure prophylaxis of rabies. When an individual is potentially exposed to the rabies virus through bites or scratches from an infected animal, HRIG is administered as a part of the rabies vaccination protocol. HRIG contains a high concentration of rabies antibodies derived from the plasma of individuals previously vaccinated against rabies. The administration of HRIG provides immediate passive immunity by supplying the patient with pre-formed antibodies, offering rapid protection against the virus while the rabies vaccine induces an active immune response. HRIG is typically administered at the site of the wound or exposure and, if possible, infiltrated into and around the wound. It is a crucial component of the rabies post-exposure prophylaxis regimen and is used in conjunction with rabies vaccinations to prevent the onset of rabies in individuals who may have been exposed to the virus.

According to DIResearch's in-depth investigation and research, the global Human Rabies Immunoglobulin (IM) market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global  manufacturers of Human Rabies Immunoglobulin (IM) include CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Bharat Serum, Shanghai RAAS, VINS etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Human Rabies Immunoglobulin (IM). Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Human Rabies Immunoglobulin (IM) market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Human Rabies Immunoglobulin (IM) market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Human Rabies Immunoglobulin (IM) industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.  

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Human Rabies Immunoglobulin (IM) Include:

CSL Behring

Grifols

Sanofi

Sichuan Yuanda Shuyang

CNBG

Kamada

CBPO

Shuanglin Bio

Weiguang Bio

Bharat Serum

Shanghai RAAS

VINS

Human Rabies Immunoglobulin (IM) Product Segment Include:

ERIG

HRIG

Human Rabies Immunoglobulin (IM) Product Application Include:

Category II Exposure

Category III Exposure

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Human Rabies Immunoglobulin (IM) Industry PESTEL Analysis

Chapter 3: Global Human Rabies Immunoglobulin (IM) Industry Porter’s Five Forces Analysis

Chapter 4: Global Human Rabies Immunoglobulin (IM) Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis

Chapter 5: Global Human Rabies Immunoglobulin (IM) Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Human Rabies Immunoglobulin (IM) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Human Rabies Immunoglobulin (IM) Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources